NVO · PEAD → 28
Novo Nordisk reported Q1 2026 results on 2026-05-06 (before market open); consensus EPS was 6.96 DKK (actual not yet in our feed).
Novo Nordisk reported Q1 2026 results on 2026-05-06 (before market open); consensus EPS was 6.96 DKK (actual not yet in our feed).
Print-day reaction was +1.98% versus the prior close, as the stock opened sharply higher and held most of the gap into the close. The overnight move to T+1 open extended a further +1.73%, suggesting no immediate fade from after-hours sellers. Over the following two trading days the price drifted an additional +1.31%, sustaining the upward bias with modest follow-through. Cumulative abnormal return of +1.26% versus SPY falls short of the +3% threshold, placing this in PEAD neutral territory; conviction registers at 28 and the holding window runs through 2026-08-03.